Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

ReportsWorldwide has announced the addition of a new report title
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation to its growing collection of premium market research reports.

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available. Current asthma treatment options are able to provide the majority of patients with a sufficient level of disease control.

Scope of the Report:

- Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape – also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing

- A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy

- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline

- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target

- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets

- Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6854

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.

- Visualize the composition of the asthma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.

- Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

- Identify commercial opportunities in the asthma deals landscape by analyzing trends in licensing and co-development deals and assessing asthma therapies that are not yet involved in deals, and may be potential investment opportunities.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/frontier-pharma-asthma-therapeutics-cytokine-and-kinase-targeted-small-molecules-and-mabs-increase-pipeline-diversity-and-dominate-first-in-class-innovation

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.